ライフサイエンスコーパス: partum

1 and at the post-partum visit (0-14 days post partum).

2 infant mortality (deaths until 90 days post partum).

3 e calls after discharge (until 6 months post partum).

4 m, and for about 75% during months 4-21 post partum.

5 at baseline and at 2, 6, and 12 months post-partum.

6 of 50 ng/mL, both during pregnancy and post partum.

7 than spermidine, except for the 5th day post-partum.

8 owed 100 women with PPCM through 1 year post-partum.

9 evels up to 4.41 mumol/l on the 3rd day post-partum.

10 he 1st, 2nd, 3rd, 4th, 5th and 15th day post-partum.

11 at presentation and at 6 and 12 months post-partum.

12 at week 1 (n = 10) and 4 weeks (n = 9) post-partum.

13 and are expected to resolve or improve post partum.

14 omen and women who were not pregnant or post partum.

15 e nipple can be symptomatic and persist post partum.

16 th age in hours over the first few days post partum.

17 o delivery and followed for four months post-partum.

18 g pregnancy or in the first four months post-partum.

19 nancy but significantly decreased 1 day post-partum.

20 he nascent epithelium at the forth week post-partum.

21 e were restored to normal levels 7 days post-partum.

22 ion through planned weaning by 6 months post partum.

23 aire at the last 4 pregnancy visits and post partum.

24 re returned to standard laboratory chow post partum.

25 groups of women at 6 weeks and 6 months post partum.

26 , every month from enrolment to 90 days post partum.

27 d economic indicators in the first year post partum.

28 stnatal day 1 and resolution by 2 weeks post partum.

29 ver, PlGF levels fell by 83% on day 1-2 post-partum.

30 rotocol) from enrollment until 24 hours post partum.

31 er and baby, but it resolves completely post partum.

32 diabetes was excluded at 4 to 16 weeks post partum.

33 the maternal circulation for many years post partum.

34 enrolled a mean (+/-SD) of 16+/-2 days post partum.

35 ng women were enrolled 5.6+/-0.8 months post partum.

36 ral vein on the same day and second day post-partum.

37 malities and died between 7 and 21 days post-partum.

38 ) and were enrolled a mean of 7.9 weeks post partum.

39 lacebo (olive oil) per day until 1 week post partum.

40 and 20 weeks' gestation through 42 days post partum.

41 e and across age groups, pregnancy, and post partum.

42 ost partum; and 3.31%, within 12 months post partum.

43 77.1% [95% CI, 75.8%-78.3%]) using them post partum.

44 occurring a mean (SD) of 12.5 (14) days post partum.

45 s discontinuation could lead to relapse post partum.

46 en diagnosed at 5 to less than 10 years post partum.

47 ental delays, at 12, 18, and 24 months' post partum.

48 cows at milkings 1, 2, 3, 4, 8, and 14 post-partum.

49 ons during home visits at 3 and 8 weeks post partum.

50 for CVD complications in the first year post-partum.

51 mercial insurance during months 3 to 12 post partum.

52 elated PPR at 42, 90, 180, and 365 days post partum.

53 use and spending during months 3 to 12 post partum.

54 nt of Health Survey at 12 to 14 months' post partum.

55 ntrol condition over the first 16 weeks post partum.

56 4 to 2018 until offspring were 21 years post partum.

57 estation and continued through 12 weeks post partum.

58 subcutaneously once daily until 6 weeks post partum.

59 ed home visits at 1, 3, 8, and 16 weeks post partum.

60 and after vaccination, at delivery and post partum.

61 of 133 Caucasian infants, three months post partum.

62 time of onset throughout pregnancy and post partum.

63 ho received Tdap vaccine within 14 days post partum.

64 period; 797 of the women were pregnant/post partum.

65 e associated with long-term morbidities post partum.

66 catchment area for follow-up of 28 days post-partum.

67 s 11 [7%] of 168 pairs; 10.3, 5.4-19.7) post partum.

68 missions for the child within 24 months post-partum.

69 nce of proposed services up to 6 weeks' post partum.

70 r 16 weeks' gestation and before 7 days post partum; 0.86 [0.74-1.00], p=0.039), early preterm delive

71 breastfeeding status at 4.5 to 6 months post-partum: 12.5% exclusive, 21.4% almost exclusive, 60.6% p

72 2 = 85.0%; 15 studies [n = 41 054]) and post partum (15.7% vs 9.6%; aOR, 1.51 [95% CI, 1.40-1.70]; I2

73 -19, 173.7 %) fetal and neonatal (1 day post partum, 161 %) TG+ compared with transgenic negative (TG

74 At 6 weeks' post partum, 174 participants in the intervention group (81%)

75 renz (EFV)-containing ART until 2 weeks post-partum (2wPP), between 9th March 2017 and 16th January 2

76 ad HIV-1 RNA data available at 50 weeks post partum: 366 (96%) in the dolutegravir-containing groups

77 events in the pregnancy group occurred post partum (4 CeADs and 1 stroke).

78 More episodes began post partum (40.1%), followed by during pregnancy (33.4%) and

79 ertensive medication use within 2 years post partum (5 postpartum time intervals) by HDP status and a

80 repregnancy weight, 7.8 kg; mean months post partum, 5.2 months) randomized to the intervention group

81 ) and late (32-36 weeks) pregnancy, and post-partum (6-10 weeks after delivery).

82 tiretroviral treatment 6 months or more post partum (7.8% and 12.0%, respectively; P=0.39).

83 By 32 weeks post partum, 96% of women in the intervention groups and 88%

84 At 42 days post partum, a major depressive episode was observed in 6.7%

85 population most likely to benefit from post-partum adherence interventions.

86 5% CI 0.5 to 1.0) in the first 12 weeks post partum after 104 livebirths, and subsequently stabilised

87 cause neonatal mortality within 28 days post-partum among babies who survived the first 24 h of life.

88 years in women who were not pregnant or post partum and 11.8 (8.4-15.3) per 1000 person-years in preg

89 were currently pregnant or up to 1 year post partum and 19 health care workers (eg, physicians, nurse

90 All pre-eclampsia-related deaths were post-partum and 50% were due to heart failure.

91 22.4) in women who were not pregnant or post partum and 8.2 (5.7-11.8) in pregnant or post-partum wom

92 cause neonatal mortality within 28 days post-partum and all-cause neonatal mortality within 28 days p

93 d in mothers and infants until 24 weeks post partum and analysed in all participants who received at

94 Plasma samples were obtained 10 days post partum and analyzed for resistance mutations.

95 mal elastic fibers in the uterine tract post partum and develop pelvic organ prolapse, enlarged airsp

96 compared neurodevelopmental outcomes of ante-partum and post-partum antiretroviral exposure in HIV-ex

97 antiretroviral exposure during both the ante-partum and post-partum phases did not result in greater

98 ed and maintained within their assigned ante-partum and post-partum phases throughout their treatment

99 etroviral treatment throughout both the ante-partum and post-partum treatment phases (adjusted means

100 s on triple antiretrovirals in both the ante-partum and post-partum treatment phases were similar to

101 yaloid vessels are persistent at 8 days post-partum and the retinal vasculature overgrows.

102 and any infant formula use at 24 weeks post partum and time to breastfeeding cessation.

103 included retention in care at 6 weeks' post partum and uptake of PMTCT services, measured by attenda

104 tal development (between days 23 and 30 post partum) and independently of the presence of testosteron

105 ith a second pregnancy within 24 months post-partum, and emergency attendances and hospital admission

106 regnancy, for 66% in the first 3 months post partum, and for about 75% during months 4-21 post partum

107 gimen of zidovudine given ante partum, intra partum, and to the newborn.

108 enrollment through pregnancy to 60 days post partum; and (3) evidence of coverage for depression scre

109 prenatal period; 1.14%, within 60 days post partum; and 3.31%, within 12 months post partum.

110 Interventions, including peri-partum antibiotics and Cesarean sections, may have unint

111 velopmental outcomes of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfe

112 persistent in the maternal circulation post-partum are associated with protection against invasive b

113 etained in care at 6 weeks and 12 weeks post partum (assessed by generalised linear mixed effects mod

114 ere aged 10 to 50 years and pregnant or post partum at death (collectively, the perinatal group) and

115 clerosis stability during pregnancy and post partum, balanced with fetal and newborn safety.

116 days prior to delivery through 28 days post partum (baseline).

117 to compare follow-up in the first year post partum between individuals with GD, type 2 diabetes, and

118 to oxytocin when used to stop excessive post-partum bleeding suspected to be due to uterine atony in

119 es major depressive episodes at 42 days post partum by about three quarters.

120 ts were made during pregnancy and early post partum by peer counsellors recruited from the same commu

121 ction during pregnancy or up to 6 weeks post partum by positive nucleic acid or antigen test, and for

122 were offered screening at 4 to 6 weeks post partum by telephone.

123 Three had myocarditis, 4 had post-partum cardiomyopathy (PPCM), and 1 had idiopathic cardi

124 t of self-test distribution: two in the post-partum care group and two female sex workers.

125 enrolled (61 in antenatal care, 117 in post-partum care, and 102 female sex workers); follow-up inte

126 ts in antenatal care, two (2%) of 91 in post-partum care, and 41 (14%) of 298 from female sex workers

127 in antenatal care, 62 (68%) of 91 from post-partum care, and 53 (83%) of 64 female sex workers.

128 s in antenatal care, 91 (86%) of 106 in post-partum care, and 64 (75%) of 85 female sex workers.

129 regnancy, antenatal, labour, birth, and post-partum care, and family planning.

130 of weather metrics, to assess pre- and post-partum climatic influences on survival on herds in popul

131 a: a health facility with antenatal and post-partum clinics and a drop-in centre for female sex worke

132 B-myb expression decreases at day 18 post partum, coincident with the initial appearance of late p

133 had a relapse within the first 6 months post partum compared with 29 women (24.2%) who intended to br

134 tly reduced depression levels 12 months post partum compared with a control.

135 reased stroke risk during pregnancy and post partum compared with their nonpregnant contemporaries.

136 ctive for the child, and when continued post partum, could enhance the quality of caregiving for the

137 Depression within 12 months post partum, defined as filling an antidepressant prescriptio

138 urther prescriptions more than 3 months post partum, depending on HDP status and antenatal medication

139 s (</=6 months post partum) with severe post-partum depression (Hamilton Rating Scale for Depression

140 ook paternity leave had reduced odds of post-partum depression (OR 0.74 [95% CI 0.70-0.78]) as did fa

141 Post-partum depression is a serious mood disorder in women th

142 igation of brexanolone in patients with post-partum depression is in progress.

143 INTERPRETATION: In women with severe post-partum depression, infusion of brexanolone resulted in a

144 (GABAA) receptors, for the treatment of post-partum depression.

145 elopment of therapies for patients with post-partum depression.

146 nd caesarean deliveries, from triage to post-partum discharge) and breast cancer care (diagnosis, che

147 scription ceases in the ovary by 3 days post partum (dpp), but continues in the testis through adulth

148 ight in meters] of 25 to 30) at 4 weeks post partum either to restrict their energy intake by 500 kca

149 e is more common in women than men, and post partum exacerbation of thyroiditis is common.

150 At 3 months post partum, exclusive breastfeeding was practised by 67% of

151 port of persistent Y chromosomal DNA in post-partum female dogs and these results suggest that fetal

152 At the 5-year post-partum follow-up, we applied an untargeted approach to i

153 table in blood samples obtained 10 days post partum from 32 percent of the women who had received int

154 In this pilot study on umbilical cords post partum from healthy non-obese (BMI = 19-25; n = 7) and o

155 wed up from pregnancy through 12 months post partum from June 27, 2016, to December 9, 2019.

156 Post-partum GD3 is not highly expressed in the brain.

157 tus, marriage type, whether pregnant or post partum, gestational age (if pregnant), and HIV risk fact

158 ortality in the 5 to less than 10 years post partum group was significantly increased, but only for B

159 2% of 244 women followed to four months post-partum had attended an HIV clinic and been assessed for

160 aemorrhage (1.49, 1.01-2.20; I(2)=37%), post-partum haemorrhage (1.29, 1.13-1.49; I(2)=41%), hyperten

161 ibiotics to reduce maternal deaths from post-partum haemorrhage and sepsis could be a highly effectiv

162 es from published work of occurrence of post-partum haemorrhage and sepsis, case fatality, and the ef

163 (10%) women were diagnosed with primary post-partum haemorrhage and were randomly assigned to receive

164 809 (3%) women were diagnosed with post-partum haemorrhage and were randomly assigned to receive

165 o intravenous oxytocin for treatment of post-partum haemorrhage in women not exposed to oxytocin duri

166 o intravenous oxytocin for treatment of post-partum haemorrhage in women receiving prophylactic oxyto

167 y events leading to maternal death from post-partum haemorrhage or sepsis after delivery.

168 mated that of 2860 maternal deaths from post-partum haemorrhage or sepsis per year in Malawi, interve

169 could reduce maternal mortality due to post-partum haemorrhage or sepsis.

170 Deaths from post-partum haemorrhage peaked 2-3 h after childbirth.

171 women in the placebo group with severe post-partum haemorrhage than those in the cholecalciferol gro

172 in acute severe bleeding (traumatic and post-partum haemorrhage).

173 For coverage of uterotonics to prevent post-partum haemorrhage, early initiation of breastfeeding (w

174 Most maternal deaths were caused by ante-partum haemorrhage, except in Ragh, where a greater prop

175 , the standard of care for treatment of post-partum haemorrhage, is not available in all settings bec

176 ytocin, the gold-standard treatment for post-partum haemorrhage, needs refrigeration, intravenous inf

177 ew of its relevance in time-to-death in post-partum haemorrhage.

178 le first-line treatment alternative for post-partum haemorrhage.

179 Retained placenta is associated with post-partum haemorrhage.

180 educe death from bleeding in trauma and post-partum haemorrhage.

181 l and caesarean births, infections, and post-partum haemorrhage.

182 r and delivery, and are more at risk of post-partum haemorrhage.

183 creasingly used ad hoc for treatment of post-partum haemorrhage; however, evidence is insufficient to

184 tion; placenta previa/abruptio placenta/ante-partum haemorrhage; multiple birth; pre-delivery LoS >=

185 Maternal depression (antepartum or post partum) has been linked to negative health-related behav

186 insertion and insertion within 36 weeks post partum have been associated with increased risk of uteri

187 aside placenta previa/abuptio placenta/ante-partum hemorrhage, further significant factors, more imp

188 and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untreated maternal HIV, and subo

189 pregnancy, neonatal thyrotoxicosis, and post-partum hyperthyroidism.

190 The lesions persisted post partum in 22 patients (88%).

191 d 28th week of pregnancy and 3-6 months post-partum in a cohort of obese and normal-weight pregnant w

192 esistance mutations at day 10 or week 6 post partum in each arm was compared with that of a historica

193 0.5 kg per week between 4 and 14 weeks post partum in overweight women who are exclusively breast-fe

194 to June 30, 2012, with 1 year follow-up post partum in the nationwide German MS and pregnancy registr

195 a median (IQR) of 5.1 (0.7-10.6) years post partum in those with HDP and 10.6 (4.2-15.8) years post

196 hose with HDP and 10.6 (4.2-15.8) years post partum in those with normotensive first pregnancies.

197 plementation arise during pregnancy and post partum, including the integration of provider training w

198 ional studies are needed to examine the post-partum increase in viremia.

199 At 16 weeks post partum, infants in the RP group had longer reported nigh

200 At 2 weeks post partum, initial intervention materials appropriate to th

201 three-part regimen of zidovudine given ante partum, intra partum, and to the newborn.

202 IUD insertion 4 days to 6 weeks or less post partum is nearly seven times that of insertion non-post

203 Adjusted HRs using women with non-post partum IUD insertion as the referent were 5.34 (95% CI,

204 At 1 day post-partum, lactationally active, distended lobuloalveoli fa

205 ro-inflammatory microenvironment during post-partum mammary involution promotes parity-associated bre

206 henotypes of EL mice are dependent upon post-partum maternal care which if systematically enhanced ca

207 mother-infant dyads within the first 15 post-partum months utilizing peptide microarray.

208 als of litters issued from IAA-positive ante partum mothers develop E-IAA with a significantly higher

209 At 6 months post-partum, mothers were asked if they had experienced sympt

210 and repeated during lactation 12 weeks post-partum (n14) and twice in NPNL women (n23 and n10, respe

211 ospholipids) and secretion from the late pre-partum/non-lactating period through the end of subsequen

212 and 11 in the third trimester; 12 were post partum, occurring a mean (SD) of 12.5 (14) days post par

213 women died between 2 weeks and 48 weeks post partum (one in maternal-antiretroviral group, two in inf

214 ed as prominent symptom dimensions with post-partum onset and were notably severe.

215 of abbreviated regimens that are begun intra partum or in the first 48 hours of life.

216 l complications occurring up to 6 weeks post partum or until hospital discharge, whichever was later.

217 Small studies reported poor post-partum outcomes among young women living with perinatal

218 0.001), and presentation after 6 weeks post-partum (p = 0.02) were associated with a lower LVEF at 1

219 ediately after birth (P0) or at 10 days post partum (P10) to determine whether neural responses follo

220 e neurological symptoms in pregnant and post-partum patients is likely to improve as we learn more ab

221 early seven times that of insertion non-post partum, perforation remains an incredibly rare event for

222 rthyroidism in pregnancy and during the post-partum period are special circumstances that need carefu

223 iated with HIV during pregnancy and the post-partum period in sub-Saharan Africa.

224 The post-partum period represents an important opportunity to opt

225 e mental disorders in pregnancy and the post-partum period.

226 ed, 235 of them during pregnancy or the post-partum period.

227 tfeeding and history of low mood in the post-partum period.

228 developed in the intrapartum and early post-partum period.

229 childhood, during pregnancy, and in the post-partum period.

230 crease in eGFR persisted into the early post-partum period.

231 attention throughout pregnancy and the post-partum period.

232 l depression (ie, during antepartum and post-partum periods) among women residing in low-income and m

233 s endogenously during pre-menstrual and post-partum periods, when decreased response to BDZ has been

234 vention should include preconception or post-partum periods.

235 ymptom onset within pregnancy and three post-partum periods.

236 Pregnant or post-partum person-years were calculated for HIV-infected and

237 xposure during both the ante-partum and post-partum phases did not result in greater developmental ri

238 d within their assigned ante-partum and post-partum phases throughout their treatment arm periods.

239 use across preconception, pregnancy and post-partum phases.

240 e, ii) late pregnant (LP), iii) one day post-partum (PP1) and iv) 7 days post-partum (PP7).

241 ne day post-partum (PP1) and iv) 7 days post-partum (PP7).

242 shold up to 4 months would increase the post-partum pregnancy-related mortality ratio by 40%.

243 ilable during pregnancy and immediately post partum, pregnancy-related loss of maternal renal functio

244 By 5 days post-partum, prominent expression became restricted to muscle

245 those with the onset of new episodes of post-partum psychosis.

246 on was significantly increased by day 1 post partum, reaching levels greater than those normally achi

247 f HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression,

248 should reflect the extended duration of post-partum risk.

249 ntly stabilised from 13 weeks to 1 year post partum (slope -0.01 log(10) copies per mL, 95% CI -0.3 t

250 e in prepartum or postpartum women, although partum status did have a significant affect on sulfadoxi

251 HIV status and partum status did not show any significant influence on

252 ll cohort and 94 817 individuals in the post-partum subcohort were analysed.

253 Women with sustained post-partum suppression were older at conception (22.9 years,

254 Post-partum surgical complications and prolonged hospital sta

255 wal paradigm, designed to mimic PMS and post-partum syndrome in a rat model.

256 Post partum, the mother-infant pairs were randomly assigned t

257 erval, 4.1 to 8.9 percent); when begun intra partum, the rate was 10.0 percent (3.3 to 21.8 percent);

258 sion of milk proteins, and by two weeks post-partum their pups are smaller in size.

259 d from the mothers weekly until 4 weeks post partum then monthly.

260 Extending the WHO 42-day post-partum threshold up to 4 months would increase the post-

261 however, whether treatment can prevent post-partum thyroiditis in women who are or have been antibod

262 Post-partum thyroiditis is substantially more frequent in wom

263 Post-partum thyroiditis occurs in 5-10% of women, and many of

264 ir newborns weekly for up to 3-6 months post-partum, to document cases of acute respiratory illness (

265 ent throughout both the ante-partum and post-partum treatment phases (adjusted means 80.64 [95% CI 77

266 retrovirals in both the ante-partum and post-partum treatment phases were similar to those for childr

267 This might be because ante-partum triple antiretroviral protection of the health of

268 ed a prescription in the first 3 months post partum, up to 55.9% (95% CI, 46.2%-66.1%) required furth

269 ective of this study was to monitor the post-partum variation of polyamine content, in ovine and capr

270 (20.4 years, 18.8-22.2), or persistent post-partum viraemia (19.0 years, 17.7-20.5).

271 ssion were also strong risk factors for post-partum viraemia.

272 natal HIV infection have a high risk of post-partum viraemia.

273 omen in this population at risk of poor post-partum virological control.

274 ion, at 36 weeks' gestation, and at the post-partum visit (0-14 days post partum).

275 s were lost to follow-up, and the final post-partum visit was on Aug 6, 2020.36 (9%) of 399 participa

276 less than 50 copies per mL at the first post-partum visit, and the primary safety outcome was the occ

277 events in mothers and infants until the post-partum visit.

278 rnal mood between delivery and 6 months post-partum was associated with an increased risk of infantil

279 ing therapy reinitiation within 1 month post partum was associated with lower odds of early postpartu

280 ood glucose, and increased attention to post-partum weight management.

281 During farm visits, cows within 21 days post-partum were categorized in one of three clinical present

282 ring during pregnancy and up to 42 days post partum were defined as pregnancy related.

283 te risks of depression within 12 months post partum were estimated using Cox proportional hazards reg

284 HIV status who died during pregnancy or post partum were HIV infected.

285 All women were followed up for 24 weeks post partum, when they completed an exit questionnaire that a

286 an LVEDD >/=6.0 cm recovered by 1 year post-partum, whereas 91% with both a baseline LVEF >/=0.30 an

287 ntinued evaluation at 1, 2, and 3 years post partum will be conducted to assess the long-term outcome

288 referred female inpatients (</=6 months post partum) with severe post-partum depression (Hamilton Rat

289 data prospectively for all pregnant or post-partum women admitted to the obstetric department.

290 rates were compared between pregnant or post-partum women and women who were not pregnant or post par

291 at roughly 24% of deaths in pregnant or post-partum women are attributable to HIV in sub-Saharan Afri

292 e neurological symptoms in pregnant and post-partum women could be caused by exacerbation of a pre-ex

293 HIV-infected pregnant or post-partum women had around eight times higher mortality tha

294 PrEP implementation for pregnant and post-partum women lags behind implementation for other high-r

295 7, and June 13, 2018, 9376 pregnant and post-partum women were assessed for behavioural risk factors

296 tenofovir to HIV-negative pregnant and post-partum women with a substantial risk of HIV acquisition.

297 3) per 1000 person-years in pregnant or post-partum women.

298 o the needs of HIV-infected pregnant or post-partum women.

299 artum and 8.2 (5.7-11.8) in pregnant or post-partum women.

300 ral load trajectory groups in the first post-partum year after livebirths.